PRESS RELEASE: WILEX AG: WILEX subsidiary Heidelberg Pharma receives research grant from the European Union
PRESS RELEASE: WILEX AG: WILEX subsidiary Heidelberg Pharma receives research grant from the European Union
DGAP-News: WILEX AG / Key word(s): Financing WILEX AG: WILEX subsidiary Heidelberg Pharma receives research grant from the European Union
2015-02-25 / 07:03
=--------------------------------------------------------------------
PRESS RELEASE
WILEX subsidiary Heidelberg Pharma receives research grant from the European Union
- Heidelberg Pharma is part of the European Training Network MAGICBULLET consortium for the development of new chemistry-driven concepts for anti-tumour therapies
Munich, Germany, 25 February 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary Heidelberg Pharma has been awarded a research grant from the European Union as part of the European Training Network (ETN) MAGICBULLET. The European Union supports promising research projects within the Horizon 2020 Framework Programme for Research and Innovation and has granted ETN MAGICBULLET a total of EUR 3.75 million for years 2015-2018 for the development of new chemistry-driven concepts for anti-tumour therapies.
Heidelberg Pharma is part of the ETN MAGICBULLET consortium which consists of seven academic research groups from Germany, Italy, Hungary and Finland, and two pharmaceutical companies (Heidelberg Pharma, Germany and Exiris, Italy). The aim of the consortium is to develop and validate an array of new peptide-drug conjugates combining tumour-specific peptides with potent cytotoxic drugs. Heidelberg Pharma's task is to identify, modify and validate tumour-specific peptide-drug conjugates based on its expertise in linker technology as well as to investigate the biological activity in vitro and in vivo.
Dr Jan Schmidt-Brand, CEO/CFO of WILEX AG and Managing Director of Heidelberg Pharma GmbH, commented: "We are pleased that MAGICBULLET was selected for the HORIZON 2020 programme and we look forward to an intensive and fruitful collaboration with our MAGICBULLET partners. Peptide-drug conjugates are promising new concepts for the therapy of different tumour types."